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Original article
Hypertension is a key risk factor for cardiovascular disease, 
the most important cause of morbidity and mortality 
worldwide.1 The detection and subsequent management 
of hypertension requires appropriate monitoring, and self-
monitoring of blood pressure (SMBP) is increasingly used for 
this purpose with endorsement by guidelines worldwide.2–4 
Compared to office blood pressure measurement, home 
readings better predict end organ damage, provide a more 
accurate diagnosis of hypertension, and improve patient 
involvement in their own care.5–7
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BACKGROUND
Self-monitoring of blood pressure better predicts prognosis than clinic 
measurement, is popular with patients, and endorsed in hypertension 
guidelines. However, there is uncertainty over the optimal self-
monitoring schedule. We therefore aimed to determine the optimum 
schedule to predict future cardiovascular events and determine “true” 
underlying blood pressure.
METHODS
Six electronic databases were searched from November 2009 (updating a 
National Institute for Health and Care Excellence [NICE] systematic review) 
to April 2017. Studies that compared aspects of self-monitoring schedules 
to either prognosis or reliability/reproducibility in hypertensive adults were 
included. Data on study and population characteristics, self-monitoring 
regime, and outcomes were extracted by 2 reviewers independently.
RESULTS
From 5,164 unique articles identified, 25 met the inclusion criteria. 
Twelve studies were included from the original NICE review, making 
a total of 37 studies. Increasing the number of days of measurement 
improved prognostic power: 72%–91% of the theoretical maximum 
predictive value (asymptotic maximum hazard ratio) was reached 
by 3  days and 86%–96% by 7  days. Increasing beyond 3  days of 
measurement did not result in better correlation with ambulatory 
monitoring. There was no convincing evidence that the timing or 
number of readings per day had an effect, or that ignoring the first day’s 
measurement was necessary.
CONCLUSIONS
Home blood pressure should be measured for 3  days, increased to 7 
only when mean blood pressure is close to a diagnostic or treatment 
threshold. Other aspects of a monitoring schedule can be flexible to 
facilitate patient uptake of and adherence with self-monitoring.
Keywords: blood pressure; blood pressure monitoring; hypertension; 
regression dilution; schedule; self-monitoring; systematic review.
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Despite the growing popularity of SMBP, there is little 
agreement as to the optimal self-monitoring schedule. The 
Japanese Society of Hypertension guidelines recommend 2 
readings on each occasion, using the mean of the 2 over 5–7 days.8 
The European Society of Hypertension, along with the American 
Heart Association and the American Society of Hypertension 
and National Institute for Health and Care Excellence (NICE), 
recommend that blood pressure (BP) should be measured on 
at least 3–4  days and preferably on 7 consecutive days in the 
morning and evening, with 2 measurements per occasion taken 
1–2 minutes apart. The readings taken on the first day should 
be discarded and then the average of the remaining readings 
used.2,3,9 There are no separate schedules recommended for 
ongoing management of patients with hypertension once the 
initial diagnosis has been made.
This study aimed to assess the evidence for these various 
guideline recommendations using the systematic search 
undertaken for the NICE (2011) Hypertension Guidelines2 
as a starting point, and updating and reappraising the 
literature.
METHODS
Data sources and searches
Electronic databases (Cochrane Central Register of 
Controlled Trials [The Cochrane Library, Wiley] (issue 3, 
March 2017), Medline [OvidSP] (1946–present, in process), 
Embase [OvidSP] (1974–present), CINAHL [EBSCOhost] 
(1980–present), Science Citation Index [Web of Knowledge] 
(1945–present), and Conference Proceedings Citation Index–
Science [Web of Knowledge] (1945–present)) were searched 
up to April 2017, for articles published from November 2009 
onward based on a search strategy developed for the NICE 
Hypertension Guidelines.2 The original NICE search was of 
Medline, Embase, CINAHL, and the Cochrane Library from 
inception to November 2010 and the update search dates 
were chosen with some overlap to ensure relevant studies 
would not be missed. The search strategy for Medline can 
be found in Supplementary Appendix 1, which was then 
adapted for the other databases.
Study selection
Two reviewers independently reviewed the titles and 
abstracts of potentially relevant articles for inclusion. Full 
papers of potentially eligible articles resulting from the 
search plus all included articles from the NICE review were 
then assessed.
All study design types were eligible for inclusion. Studies 
must have assessed SMBP defined as BP measurement 
by a patient or carer, without the involvement of a health 
professional. It was anticipated that included studies would 
compare one or more of the following protocol components: 
number, timing, frequency, and duration of measurements 
and whether any readings should be discarded, but included 
all studies that compared any aspects of self-monitoring 
schedules. Studies that assessed regimes in terms of BP 
variability, machine validation studies, those containing 
inadequate description of the self-monitoring protocol, or 
where self-monitoring was not conducted using an upper 
arm device were excluded.
Participants of interest were adults (18  years and older) 
with treated or untreated hypertension, who may or may 
not have had a comorbid disease. Reliability/reproducibility 
studies were included where at least some of the participants 
had hypertension or were being assessed to confirm suspicion 
of hypertension (e.g., where a previous clinic reading had 
indicated hypertension), and similarly prognostic studies 
(which were all conducted in the general population) where 
at least some participants either had hypertension or were 
treated with antihypertensive medication.
Articles written in a language other than English were 
translated to assess eligibility.
Data extraction and quality assessment
Data from each article were extracted independently by 
at least 2 reviewers using piloted forms (Supplementary 
Appendix 2). Information collected included study (e.g., 
country, hypothesis) and sample (e.g., sample size, age, 
comorbidities) characteristics, self-monitoring regime 
details (e.g., frequency, duration, whether devices used 
were validated), and outcome measures (see later). Any 
discrepancies were resolved by consensus.
A priori outcomes of interest varied with the type of study
 (1) Prognostic studies: mortality, stroke, myocardial infarction, 
angina, and heart failure or composites thereof.
 (2) Reliability/reproducibility studies: reproducibility of 
SMBP or correlations with ambulatory blood pressure 
measurement (ABPM) or office blood pressure 
measurement.
Methodological quality was assessed using an adaptation of 3 
validated checklists: Effective Public Health Practice Project, 
Downs and Black, and Quality Assessment of Diagnostic 
Accuracy Studies  (QUADAS-2).10–12 Additional questions 
about the validation status of the BP monitoring equipment 
used in each study were incorporated, for which we consulted 
the dabl Educational Trust and British and Irish Hypertension 
Society websites13,14 rather than rely on author-reported 
validation status (Supplementary Appendix 3 provides details 
of the methodological quality checklist applied).
Data synthesis and analysis
Imprecision in a measurement makes associations, 
such as hazard ratios (HRs) or correlations, harder to 
observe. Averaging over several measurements can reduce 
imprecision. Hence, a single imprecise measurement will 
show a weaker apparent association with an outcome, but 
increasing the number of measurements increases the 
apparent association.
To enable a consistent measure of comparison, the 
adjusted HR per 5  mm Hg increase in systolic BP was 
calculated for prognostic studies across the number of days 
of readings they considered. Study-specific curves for HR 
against number of days (n) were estimated by assuming that 
the reciprocal of estimated log HR was linear in 1/n, and 
for estimated correlation coefficient against n by assuming 
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that the reciprocal of correlation squared was linear in 1/n. 
These relationships were derived from standard results for 
linear regression dilution, which have been shown to apply 
approximately for HRs, under independence assumptions, 
when censoring is present and the sample size is large15 
(Supplementary Appendix 4 provides a further explanation 
of the method of analysis used, including the approach to 
regression dilution). For each study, the “maximum log 
hazard ratio” was defined as the asymptotic maximum 
of the fitted curve on the log HR scale (i.e., the best log 
HR that could theoretically be achieved given an infinite 
number of days for measurement) and the fitted log HR 
at day 3 and day 7 is reported as a percentage of this 
maximum.
For reliability/reproducibility studies, the correlations 
reported between systolic and diastolic SMBP and ABPM 
as the reference standard were summarized. The remaining 
studies, in particular reliability studies that reported 
correlations with measures other than ABPM, were 
considered too dissimilar to group.
RESULTS
A total of 5,164 unique citations were identified of which 
297 were assessed in detail along with 13 articles from the 
NICE search (Figure 1). Thirty-seven studies proved eligible 
for inclusion in the analysis comprising 25 from the update 
and 12 from the original NICE search (the remaining 
Database searching
5164 citations
After title screening
1525 citations
(29.5%)
After abstract 
screening
297 full text papers 
(5.8%)
Data extraction
44 papers
(0.9%)
In-depth review
25 studies
(0.5%)
NICE Guideline review
13 papers 
Data extraction
13 papers
In-depth review
12 studies
Final analysis
37 studies
Studies excluded from in-
depth review
Duplicate data to included 
paper: 1
Studies excluded from in-depth 
review
No relevant data: 8
Duplicates of NICE papers: 5
Only applicable to haemodialysis 
patients: 2
No comparison of different home 
BP monitoring schedules: 1
No hypertensives in population: 1
BP assessed in terms of 
variability, not mean: 2
TOTAL: 19
Studies excluded from data 
extraction
253 not relevant on basis of 
reading full article
Figure 1. Filtering of papers from searching to synthesis. 
Abbreviations: BP, blood pressure; NICE, National Institute for Health and Care Excellence.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajh/advance-article-abstract/doi/10.1093/ajh/hpy185/5298703 by U
C
L (U
niversity C
ollege London) user on 05 February 2019
4 American Journal of Hypertension
Hodgkinson et al.
article from the NICE review provided only duplicate 
data). Participants in the included studies (Supplementary 
Table 1) were drawn from 18 different countries and varied 
markedly in terms of mean age (range 40–70 years), gender 
(percentage male 26%–100%), sample size (43–21,591), and 
the proportion with hypertension and/or on antihypertensive 
medication (0%–100%).
Of the 37 articles, 10 were prognostic and 27 were 
reliability/reproducibility studies. The wide range of aspects 
of monitoring schedule assessed in the included studies is 
shown in Supplementary Table 2. Owing to the heterogeneity 
of the self-monitoring protocols, and the variability in the 
clinical outcomes and analyses in the eligible studies, meta-
analysis was not possible.
Methodological issues
All studies had some degree of methodological flaw 
(or lack of clarity in what was reported), with 16 (43%) 
studies not clearly using validated devices throughout 
(Supplementary Table 1). Although selection criteria of 
participants were generally clear, only 16 (43%) studies used 
selection methods likely to avoid bias (Supplementary Table 
2). Attrition reporting provided reasons for dropouts but 
typically not the characteristics thereof. Validation (from 
monitor memory or telemonitoring) of self-monitored 
readings was only clear and adequate in 10 studies. Reporting 
of results was generally adequate.
Prognostic studies
The 10 prognostic studies analyzed cohort data from 
Japan (Ohasama and home blood pressure measurement 
with Olmesartan Naive patients to Establish Standard 
Target blood pressure study [HONEST]), Finland (FINN 
Home), and Greece (Didima), or meta-analyzed data from 
Ohasama, FINN Home, and an additional Japanese cohort, 
Tsurugaya, which had not been published separately in a 
format we could extract relevant data from.16,17 There was 
overlap of populations within each cohort but differences in 
type of regime considered and/or the outcomes assessed. All 
participants in the prognostic studies were sampled from a 
general population. Three studies (Supplementary Table 1) 
had prediction of stroke/transient ischemic attack as the 
main outcome, whereas 4 used cardiovascular-related events, 
one considered both types of outcome separately, and 2 used 
composite cardiovascular end points including stroke.
Figure 2 shows the adjusted log HR per 5 mm Hg increase 
in systolic BP for each of the 5 studies (1 provided only 
unadjusted HRs with confidence intervals) that considered 
how outcome varied by length of monitoring in days (see 
also Table 1). HRs increased with additional days of readings 
across the studies with a flattening of the curves after 1 
week for the 2 studies with longer follow-up and similar 
shaped curves for the shorter studies. However, confidence 
intervals overlapped between the most and least predictive 
measurement regimes (in terms of days of monitoring).
In Figure 2 the dotted line represents the maximum log 
HR for the 5 prognostic studies: 86%–96% of the maximum 
predictive value (asymptotic maximum HR, based on an 
estimate given infinite number of days measurement) was 
achieved by 7 days, and 72%–91% by 3 days.
Few data on the impact of time of day were available, but 
suggested that there was a maximum difference in HR of 
0.09 per 5 mm Hg increase in systolic BP with overlapping 
confidence intervals between morning and/or evening 
measurements. There was also no convincing difference in 
prognostic ability when using the first and/or the second 
measurement on each occasion (Table 2).
Considering the total number of readings added little to 
the results for number of days, reflecting the limited data on 
readings per day (Supplementary Table 3). Only 1 prognostic 
study considered the effect of omitting first-day readings from 
the analysis, which made no difference to the HR (Table 3).
Analysis of reliability/reproducibility studies
Participants in the 27 reliability/reproducibility studies 
were largely either treated or untreated patients with 
hypertension, though populations ranged from heart 
transplant recipients and renal outpatients to company 
volunteers and attendees at a health education program 
(Supplementary Table 1). Three studies shared populations 
with the Japanese and Finnish prognostic studies.
Of the 20 studies considering reliability/reproducibility, 15 
reported correlations with ABPM as the reference standard, 
8 using mean daytime ABPM, 5 using 24-hour ABPM, and 
2 using both daytime and 24-hour ABPM. These 15 studies 
were included in the remainder of the analyses.
The correlation between cumulative mean home systolic 
BP and diastolic blood pressure from 1 to 7  days of 
monitoring with ABPM as the comparator measurement is 
shown in Figure 3 (analysis restricted to those studies (n = 5) 
with correlations for at least 3 different counts of days; the 
dotted line represents the maximum correlation coefficient) 
and Table 4. Here the curves were very flat and there was 
no convincing increase in correlation after the fourth day of 
monitoring. Better than 90% of the maximum correlation 
with ABPM was achieved by 3  days. In many correlation 
studies, numbers of participants were small and confidence 
intervals were wide, but this pattern was observed even in 
larger studies (n = 464).
Data could only be extracted from 3 studies to assess 
the relationship between correlation with ABPM and 
the number of readings on each occasion, time of day of 
2 readings (Figure 4 and Table 5), and total number of 
measurements (Table 6). As for the prognostic studies, 
varying the number of readings on each occasion and time 
of day of readings appeared to have little impact, while 
examining the effect of number of measurements overall 
again largely replicated the results for number of days. 
Similarly, discarding the readings from the first day of 
home monitoring made little difference to correlation with 
ABPM, whether readings more than 3 days or 1 week were 
being considered (Table 3).
Three studies considered particular aspects of monitoring 
schedules uniquely—the time interval between readings, 
a schedule including before-morning micturition and 
afternoon readings vs. 1 involving post-morning micturition 
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and evening readings, and resting for 5 minutes before 
readings vs. not resting. However, the complexity of the 
schedule comparison in 1 study and the small sample size 
of the other studies prevented drawing any firm conclusions.
No study provided evidence on the timings of readings in 
relation to medications, how frequently monitoring should 
be repeated, or on whether fewer readings may be required 
for routine ongoing management.
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Figure 2. Log hazard ratios per 5 mm Hg for prognostic outcomes by cumulative numbers of days of self-monitoring. *Values from Stergiou (2010) are 
unadjusted hazard ratios (HRs).
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DISCUSSION
Summary of main findings
The literature has been comprehensively reviewed, finding 
37 studies relating self-monitoring regimes to prognosis and/
or correlation to reference standard, with the aim of making 
evidence-based recommendations for future practice. For 
prognostic studies, only a small increase in precision was 
gained from undertaking more than 3  days of readings 
and the results from correlation studies were similar. Such 
differences are likely only to impact on clinical decision 
making around diagnostic or treatment thresholds. There 
was no convincing difference in terms of how many readings 
were taken per day, whether morning and/or evening 
measures are used, or whether the first day was removed.
Strengths and limitations of the study
This review used a comprehensive search strategy in multiple 
databases and all languages, incorporating hand searching, 
and is unlikely to have missed relevant articles. A thorough 
assessment of methodological quality was undertaken 
including assessment of the validation status of the monitors 
used.13,14 By estimating study-specific curves for either HR or 
correlation coefficient against regime, the available data were 
synthesized in a robust form, despite any heterogeneity. By 
including a broad range of potential elements of monitoring 
schedules, this provides the most complete evidence to date 
on which to base recommendations.
The key weakness of this review is the paucity of studies 
of prognosis. Despite several different publications, only 
4 sources of participants make up the full data set. While 
covering populations from Japan, Finland, and Greece, these 
data are lacking large relevant populations, in particular of 
South Asian and African/African Caribbean origin. Though 
used in a combined population, 1 cohort (Tsurugaya)16,17 
was included, which has not been published separately in a 
format we could extract the relevant data from, and hence 
was only included as part of the Niiranen et al. meta-analysis.
Furthermore, the findings of small differences in both 
prognostic ability and correlation between different 
regimes must be tempered by the heterogeneity of design 
and methodological flaws identified in some studies. 
This reflected a lack of uniformity of method used 
between studies, and precluded comparison of more 
diverse regimes of measurement across multiple studies. 
Similarly, several studies used unvalidated equipment 
(Supplementary Table 1).
Table 3. Effect of discarding the first day of measurement across all types of study (systolic blood pressure)
Study (first author; publication date) Comparator N Using all measurements
Omitting measurements  
from the first day
3 days of home measurement Correlation with ABPM (95% confidence interval)
 Johansson (2010) 24-hour ABPM 464 0.88 (0.86–0.90) 0.89 (0.87–0.91)
 Stergiou (1998) Daytime ABPM 189 0.68 (0.60–0.75) 0.67 (0.58– 0.74)
 Verberk (2006) Daytime ABPM 216 0.60 (0.51–0.68) 0.60 (0.51–0.68)
24-hour ABPM 216 0.66 (0.58–0.73) 0.69 (0.61–0.75)
4 days of home measurement Correlation with ABPM (95% confidence interval)
 Di Monaco (2016) Daytime ABPM 310 0.59 (0.51–0.65) 0.57 (0.49–0.64)
24-hour ABPM 310 0.59 (0.51–0.66) 0.57 (0.49–0.64)
 Stergiou (1998) Daytime ABPM 189 0.70 (0.62–0.77) 0.69 (0.61–0.76)
 Verberk (2006) Daytime ABPM 216 0.62 (0.53–0.70) 0.62 (0.53–0.70)
24-hour ABPM 216 0.68 (0.60–0.75) 0.69 (0.61–0.75)
1 week of home measurementa Correlation with ABPM (95% confidence interval)
 Johansson (2010) 24-hour ABPM 464 0.89 (0.87–0.91) 0.87 (0.85– 0.89)
 Nunan (2015) Daytime ABPM 203 0.67 (0.59–0.74) 0.68 (0.60–0.75)
 Stergiou (1998) Daytime ABPM 189 0.71 (0.63–0.77) 0.71 (0.63–0.77)
 Verberk (2006) Daytime ABPM 216 0.65 (0.57–0.72) 0.65 (0.57–0.72)
24-hour ABPM 216 0.70 (0.62–0.76) 0.71 (0.64–0.77)
1 week of home measurementa Hazard ratio for future CVD (95% confidence interval)
 Niiranen (2011) Future CVD 162b 1.11 (1.06–1.16) 1.11 (1.06–1.16)
Abbreviations: ABPM, ambulatory blood pressure measurement; CVD, cardiovascular disease.
a 1 week refers to 7 days of home measurement, except for Stergiou (1998) where home monitoring was only conducted for 6 days.
b162 CVD events.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajh/advance-article-abstract/doi/10.1093/ajh/hpy185/5298703 by U
C
L (U
niversity C
ollege London) user on 05 February 2019
American Journal of Hypertension 9
Schedules for Self-monitoring Blood Pressure
Comparisons with existing literature
One previous systematic review over a decade ago including 
4 reliability/reproducibility studies19 considered multiple 
aspects of monitoring schedules but did not include any 
prognostic studies. In comparison, the current analysis includes 
10 prognostic studies and 27 reliability/reproducibility studies. 
More recently, Niiranen et al.20 combined 3 cohorts (2 Japanese 
and 1 Finnish) with consideration of prognosis in terms of 
number of days per week, but did not assess correlation data or 
other aspects of a monitoring regime, as the current work has.
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Figure 3. Correlation coefficient between ambulatory blood pressure measurement (ABPM) and self-monitoring of blood pressure (SMBP) by 
cumulative number of days of self-monitoring.
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Despite the heterogeneity and variable methodological 
quality of the evidence reviewed, many authors of 
the individual included studies drew strong and clear 
conclusions from their results. This was in spite of many 
HRs fully overlapping between apparently optimum and 
less optimum regimes. Subsequent guidelines from NICE, 
Europe, and the United States followed these conclusions 
in terms of recommendations on the number of days, the 
number of readings to take on each occasion, a preference for 
measuring in both the morning and evening, which values 
to discard, and total number of measurements.2–4 However, 
we found that for most aspects of monitoring schedules, 
evidence was either missing or at best ambivalent, suggesting 
excessive influence of the interpretation of individual studies 
by the study authors rather than the observed results.
Linked qualitative work by our group suggests that 
patients value flexibility in regime, and given the lack of 
evidence underpinning fixed regimes, incorporating such 
flexibility in future guideline iterations seems sensible.21 This 
might increase uptake and compliance,22 thus facilitating 
further implementation of self-monitoring.
Implications for clinical practice
The relatively modest benefit from more than 3  days 
of readings or of any particular quantity or timing of 
readings within these 3 days suggests that more protracted 
schedules are only likely to be worthwhile around diagnostic 
or treatment thresholds. Given the widespread use of 
telemonitoring, automated patient feedback could be used to 
Figure 4. Correlation coefficient between ambulatory blood pressure measurement (ABPM) and self-monitoring of blood pressure (SMBP) by time 
of day of self-monitoring. The comparison in Stergiou (1998) is between first morning vs. first day; all other comparisons are between all morning, all 
evening or all readings.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajh/advance-article-abstract/doi/10.1093/ajh/hpy185/5298703 by U
C
L (U
niversity C
ollege London) user on 05 February 2019
American Journal of Hypertension 13
Schedules for Self-monitoring Blood Pressure
Ta
b
le
 5
. 
C
or
re
la
tio
n 
w
ith
 a
m
bu
la
to
ry
 b
lo
od
 p
re
ss
ur
e 
m
ea
su
re
m
en
t (
A
B
P
M
) 
fo
r 
re
lia
bi
lit
y/
re
pr
od
uc
ib
ili
ty
 s
tu
di
es
 a
cr
os
s 
nu
m
be
r 
of
 r
ea
di
ng
s 
on
 e
ac
h 
oc
ca
si
on
 a
nd
 ti
m
e 
of
 d
ay
S
tu
d
y 
 
(fi
rs
t 
au
th
o
r;
 
p
u
b
lic
at
io
n
 
d
at
e)
M
ea
su
re
m
en
t 
sc
h
ed
u
le
C
o
m
p
ar
at
o
r
N
C
o
rr
el
at
io
n
 c
o
ef
fi
ci
en
t 
b
et
w
ee
n
 h
o
m
e 
sy
st
o
lic
/d
ia
st
o
lic
 B
P
 a
n
d
 t
h
e 
co
m
p
ar
at
o
r 
m
ea
su
re
m
en
t
N
u
m
b
er
 o
f 
re
ad
in
g
s 
o
n
 e
ac
h
 o
cc
as
io
n
T
im
e 
o
f 
d
ay
A
ll 
fi
rs
t 
m
ea
su
re
m
en
ts
A
ll 
se
co
n
d
 
m
ea
su
re
m
en
ts
A
ll 
m
ea
su
re
m
en
ts
A
ll 
m
o
rn
in
g
 
m
ea
su
re
m
en
ts
A
ll 
ev
en
in
g
 
m
ea
su
re
m
en
ts
A
ll 
m
ea
su
re
m
en
ts
Jo
ha
nn
so
n 
(2
01
0)
7 
da
ys
 (
2 
re
ad
in
gs
 in
 th
e 
m
or
ni
ng
 a
nd
  
2 
re
ad
in
gs
 in
 th
e 
ev
en
in
g 
on
 e
ac
h 
da
y)
24
-h
ou
r A
B
P
M
T
im
in
g 
in
 r
el
at
io
ns
hi
p 
to
 S
M
B
P
 u
nc
le
ar
46
4
0.
89
/0
.8
7
0.
89
/0
.8
7
0.
89
/0
.8
7
0.
87
/0
.8
5
0.
88
/0
.8
7
0.
89
/0
.8
7
S
te
rg
io
u 
(1
99
8)
a
3 
w
or
k 
da
ys
 p
er
 w
ee
k 
fo
r 
2 
w
ee
ks
  
(2
 r
ea
di
ng
s 
in
 th
e 
m
or
ni
ng
 a
nd
  
2 
re
ad
in
gs
 in
 th
e 
ev
en
in
g 
on
 e
ac
h 
da
y)
D
ay
tim
e 
A
B
P
M
S
om
e 
A
B
P
M
 fi
rs
t a
nd
 
so
m
e 
S
M
B
P
 fi
rs
t, 
on
e 
af
te
r 
th
e 
ot
he
r
18
9
0.
59
/0
.6
4
 
0.
62
/0
.6
7
0.
62
/0
.6
7
 
0.
66
/0
.7
0
V
er
be
rk
 
(2
00
6)
7 
da
ys
 (
3 
re
ad
in
gs
 in
 th
e 
m
or
ni
ng
 a
nd
  
3 
re
ad
in
gs
 in
 th
e 
ev
en
in
g,
 w
ith
 th
e 
 
fir
st
 o
f e
ac
h 
tr
ip
lic
at
e 
di
sc
ar
de
d)
D
ay
tim
e 
A
B
P
M
T
im
in
g 
vs
. S
M
B
P
 
un
cl
ea
r
21
6
 
 
 
0.
63
/0
.6
5
0.
58
/0
.6
0
0.
65
/0
.6
6
 
24
-h
ou
r A
B
P
M
T
im
in
g 
vs
. S
M
B
P
 
un
cl
ea
r
21
6
 
 
 
0.
69
/0
.6
9
0.
64
/0
.6
2
0.
70
/0
.6
9
A
bb
re
vi
at
io
n:
 S
M
B
P,
 s
el
f-
m
on
ito
rin
g 
of
 b
lo
od
 p
re
ss
ur
e.
a S
tu
dy
 r
ep
or
ts
 fi
rs
t b
lo
od
 p
re
ss
ur
e 
(B
P
),
 fi
rs
t d
ou
bl
e 
(s
am
e 
as
 fi
rs
t m
or
ni
ng
),
 a
nd
 d
ay
 1
, r
at
he
r 
th
an
 a
ll 
m
ea
su
re
m
en
ts
.
Ta
b
le
 6
. 
C
or
re
la
tio
n 
w
ith
 a
m
bu
la
to
ry
 b
lo
od
 p
re
ss
ur
e 
m
ea
su
re
m
en
t (
A
B
P
M
) 
fo
r 
re
lia
bi
lit
y/
re
pr
od
uc
ib
ili
ty
 s
tu
di
es
 a
cr
os
s 
nu
m
be
r 
of
 m
ea
su
re
m
en
ts
S
tu
d
y.
 
(fi
rs
t 
au
th
o
r;
 
p
u
b
lic
at
io
n
 d
at
e)
M
ea
su
re
m
en
t 
sc
h
ed
u
le
C
o
m
p
ar
at
o
r
N
C
o
rr
el
at
io
n
 c
o
ef
fi
ci
en
t 
b
et
w
ee
n
 h
o
m
e 
sy
st
o
lic
/ d
ia
st
o
lic
 B
P
 a
n
d
 t
h
e 
co
m
p
ar
at
o
r 
m
ea
su
re
m
en
t
1
2
3
4
5
6
7
8
9
10
11
12
16
20
24
28
Jo
ha
nn
so
n 
(2
01
0)
7 
da
ys
 (
2 
re
ad
in
gs
 in
 th
e 
m
or
ni
ng
 a
nd
 2
 r
ea
di
ng
s 
in
 th
e 
ev
en
in
g 
on
 e
ac
h 
da
y)
24
-h
ou
r A
B
P
M
T
im
in
g 
in
 
re
la
tio
ns
hi
p 
to
 
S
M
B
P
 u
nc
le
ar
46
4
 
 
 
0.
84
/0
.8
2
 
 
 
0.
87
/0
.8
4
 
 
 
0.
88
/0
.8
5
0.
88
/0
.8
6
0.
89
/0
.8
6
0.
89
/0
.8
7
0.
89
/0
.8
7
S
te
rg
io
u 
 
(1
99
8)
3 
w
or
k 
da
ys
 p
er
 w
ee
k 
fo
r 
2 
w
ee
ks
 (
2 
re
ad
in
gs
 
in
 th
e 
m
or
ni
ng
 a
nd
 2
 
re
ad
in
gs
 in
 th
e 
ev
en
in
g 
on
 e
ac
h 
da
y)
D
ay
tim
e 
A
B
P
M
S
om
e 
A
B
P
M
 fi
rs
t 
an
d 
so
m
e 
S
M
B
P
 
fir
st
, o
ne
 a
fte
r 
th
e 
ot
he
r
18
9
0.
59
/0
.6
4
0.
62
/0
.6
7
 
0.
66
/0
.7
0
 
 
 
0.
68
/0
.7
3
 
 
 
0.
68
/0
.7
5
0.
70
/0
.7
7
0.
71
/0
.7
8
0.
71
/0
.7
9
 
V
er
be
rk
  
(2
00
6)
7 
da
ys
 (
3 
re
ad
in
gs
 in
 
th
e 
m
or
ni
ng
 a
nd
 
3 
re
ad
in
gs
 in
 th
e 
ev
en
in
g,
 w
ith
 th
e 
`fi
rs
t o
f e
ac
h 
tr
ip
lic
at
e 
di
sc
ar
de
d)
D
ay
tim
e 
A
B
P
M
T
im
in
g 
vs
. S
M
B
P
 
un
cl
ea
r
21
6
 
0.
53
/0
.6
2
 
0.
53
/0
.5
9
 
 
 
0.
57
/0
.6
1
 
 
 
0.
60
/0
.6
3
0.
62
/0
.6
3
0.
63
/0
.6
6
0.
64
/0
.6
6
0.
65
/0
.6
6
24
-h
ou
r A
B
P
M
T
im
in
g 
vs
. S
M
B
P
 
un
cl
ea
r
21
6
 
0.
57
/0
.6
5
 
0.
57
/0
.6
1
 
 
 
0.
62
/0
.6
3
 
 
 
0.
66
/0
.6
6
0.
68
/0
.6
6
0.
69
/0
.6
9
0.
69
/0
.6
9
0.
70
/0
.6
9
A
bb
re
vi
at
io
n:
 S
M
B
P,
 s
el
f-
m
on
ito
rin
g 
of
 b
lo
od
 p
re
ss
ur
e.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajh/advance-article-abstract/doi/10.1093/ajh/hpy185/5298703 by U
C
L (U
niversity C
ollege London) user on 05 February 2019
14 American Journal of Hypertension
Hodgkinson et al.
inform individuals where more than 3 days of measurements 
are appropriate.
These data hold for both diagnosis and ongoing 
management. There are theoretical reasons (peaks 
and troughs of medication for example) that support 
recommendations for morning and evening readings.23 In 
terms of diagnosis, the prognostic studies did not suggest 
any particular difference in time of measurement and 
neither were differences in correlation seen dependent on 
time of day of monitoring, perhaps suggesting that such 
considerations are not paramount.
On the basis of the evidence we have synthesized, a 
pragmatic revision of current guidelines for self-monitoring 
would be that measurement of BP should be undertaken for 
3 days, whether for diagnostic purposes or when monitoring 
the effect of treatment change, unless mean blood pressure 
after 3 days is close to a treatment or diagnostic threshold 
when longer schedules—perhaps a further 3  days of 
monitoring—bring small increases in prognostic power. 
Precise timings of measurements within these days and the 
precise days of measurement are less important and might 
be varied to suit individual circumstances. There remains 
a need for more and higher quality research, particularly 
prognostic studies in diverse populations, involving 
comparison of different regimes of measurement across 
multiple studies.
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